On April 14, 2020 NOXXON Pharma N.V. (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), reported that its poster titled "Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer" has been selected for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting 2020 (Press release, NOXXON, APR 14, 2020, View Source [SID1234556320]). The presentation will include a short video and commentary by the first author, Dr. Niels Halama, from National Center for Tumor Diseases (NCT) in Heidelberg, Germany, who will present the latest pharmacodynamic, safety, survival and more mature clinical data from the trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be freely available upon registration on the AACR (Free AACR Whitepaper) website in the Virtual Poster Session section as of Monday, April 27, 2020, 06.00 p.m. CEST. The abstract will be posted online to the AACR (Free AACR Whitepaper) website on Monday, April 27, 2020.

On April 6, 2020, the Board of Directors of the AACR (Free AACR Whitepaper) had announced that due to the COVID-19 outbreak it would not organize an in-person Annual Meeting in 2020, originally scheduled for April 24-29 in San Diego, California. Instead, the AACR (Free AACR Whitepaper) will feature selected program and presentations in Virtual Annual Meetings, on April 27-28 and June 22-24.